The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer Research (AACR), as published in Clinical Cancer Research on May 15, 2025. These evidence-based updates offer important changes to surveillance protocols aimed at improving early cancer detection and care for individuals living with LFS.
The LFSA Genetic Counseling Advisory Group worked to help clearly explain the changes and updates, which include an enhanced emphasis on targeted screening by age and risk factors, as well as tailored treatment considerations for those undergoing cancer therapy. A detailed outline of the recommendations, including screening schedules for children and adults, is now available on our website’s Treatment and Preventative Screening page.
Highlights of what’s new:
- Continued use of whole-body MRI, but with increased focus on targeted organ screening
- New guidance for modifying radiation and chemotherapy in LFS patients to reduce secondary cancer risk
- Updates on colonoscopies for patients with prior radiation exposure
- Discussion of liquid biopsies, emotional support, and unique considerations for gender-diverse individuals
While there is still no standard cure for LFS, ongoing surveillance and preventive care remain the most effective tools we have. These new guidelines reinforce the importance of lifelong, tailored screening for those with a germline TP53 mutation.
We encourage you to share this information with family, friends, and healthcare providers who may benefit. Increased awareness and proactive screening can make a lifesaving difference.
- Download the 2025 AACR Screening Recommendations
- Visit the LFSA Screening Guidelines Page
- LFS Quick Fact Sheet for Medical Providers
Let’s keep the momentum going – share these recommendations and help others stay informed, proactive, and empowered.
